MELBOURNE, Australia, Nov. 15, 2017 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to provide an update on the progress of the clinical trial of its lead Cymerus™ mesenchymal stem cell (MSC) product CYP-001. [Read more…]
Off the Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis
BOTHELL, Wash., Sept. 19, 2017 — BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media (“BioLife”), announced that Cellular Biomedicine Group (NASDAQ: CBMG), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases (“CBMG”), has validated BioLife’s proprietary CryoStor freeze media for use in CBMG’s planned US Phase I clinical trial of AlloJoin, an off the shelf allogeneic stem cell therapy for knee osteoarthritis.
Mike Rice, BioLife President & CEO, commented, “We are very pleased to support CBMG in their development and potential commercialization of AlloJoin. CBMG is the leading regenerative medicine company in China, with a robust clinical pipeline and high-quality, scalable manufacturing facilities.”
In addition to this product adoption by CBMG, CryoStor and HypoThermosol®, BioLife’s companion cell storage and shipping media, have been used in at least 250 regenerative medicine applications, including several late-stage clinical trials. BioLife’s customer base has grown to over 2,000 companies, universities and clinical centers in the regenerative medicine, drug discovery and biobanking markets. [Read more…]
Dr. Saud Sadiq announced that the Tisch MS Research Center of New York will be pursuing a Phase II clinical trial exploring the use of stem cells for treatment of multiple sclerosis (MS), planned to start in this fall. The announcement followed positive results from a FDA-approved Phase I stem cell trial for MS.
In the Phase I clinical trial, MS patients received multiple spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (called MSC-NPs).
Compellingly, the Phase I trial was the first time ever that a treatment method has demonstrated reversal of established disability in MS patients.
Stem Cell Treatment for MS Reverses Disability in Patients
For more than 20 years, Dr. Saud Sadiq has aimed to merge clinical excellence with innovative research targeted at finding the cure for multiple sclerosis. Today, the Tisch MS Research Center of New York, a non-profit research center, has a close relationship with its affiliated clinical practice, the International Multiple Sclerosis Management Practice.
This partnership enables the testing of new MS treatments and accelerates the pace at which research discoveries are translated into clinical practice, as demonstrated by the center’s innovative work with use of neural progenitors derived from bone marrow mesenchymal stem cells. [Read more…]
- Patient dosing commenced in world-first Phase I trial of stem cell therapy CYP-001 in graft-versus-host disease; recruiting at six centres in the UK and Australia
- Secured $60-million-plus FUJIFILM partnership and license option for CYP-001 in GvHD
- Raised additional $10 million: $4 million equity investment from FUJIFILM and $6 million placement
- Reported positive pre-clinical data in heart attack and asthma; expanded pre-clinical pipeline to acute respiratory distress syndrome
- Filed two new patent applications with IP Australia to expand opportunities in cancer immunotherapy
- Completed pre-Investigational New Drug meeting with U.S. Food and Drug Administration Office of Cellular, Tissue and Gene Therapy; written recommendation expected by July 2017
In breaking news released earlier this month, Cynata Therapeutics Limited (ASX: CYP) announced a major world first.
The company treated a patient with steroid resistant acute graft-versus-host disease (GvHD) as part of a phase 1 clinical study of its first mesenchymal stem cell (MSC) product, CYP-001 .
Click here for the full ASX announcement: http://cynata.com/wp-content/uploads/2017/05/17.05.16.Treatment-Commences-in-Cynatas-World-First-Clinical-Trial.pdf
This is an important value catalyst for Cynata and also for the regenerative medicine industry, because it is the first time ever that a patient has been treated with an allogeneic induced pluripotent stem cell (iPSC)-derived therapeutic mesenchymal stem cell (MSC) product. [Read more…]